Skip to main content

Advertisement

Table 5 SUV and changes in SUV based on molecular phenotypes

From: Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

  No. of Pts Pre-SUV * Post-SUV * ΔSUV% * HPR (%)
ER      
   Positive 38 6.4 ± 3.3 3.7 ± 2.1 30 ± 57 3 (7.9)
   Negative 40 8.6 ± 4.9 4.1 ± 3.1 48 ± 37 11 (27.5)
   P = 0.047 P = 0.936 P = 0.038 P = 0.037†
PR      
   Positive 30 6.5 ± 3.3 3.5 ± 2.4 36 ± 63 3 (10.0)
   Negative 48 8.2 ± 4.8 4.2 ± 2.8 42 ± 37 11 (22.9)
   P = 0.187 P = 0.347 P = 0.837 P = 0.226†
HER2      
   Positive 17 6.8 ± 3.2 3.2 ± 2.6 51 ± 36 5 (29.4%)
   Negative 61 7.7 ± 4.6 4.1 ± 2.7 36 ± 51 9 (14.8%)
   P = 0.818 P = 0.247 P = 0.189 P = 0.164†
Triple negativity      
   TNBC 26 9.8 ± 5.3 5.0 ± 3.0 42 ± 35 6 (23.1)
   Non-TNBC 52 6.4 ± 3.2 3.4 ± 2.3 38 ± 54 8 (15.4)
   P = 0.008 P = 0.076 P = 0.799 P = 0.404†
Molecular phenotype      
   Luminal A/B 40 6.3 ± 3.3 3.6 ± 2.2 33 ± 57 3 (7.5)
   HER2 12 6.6 ± 3.2 2.8 ± 2.6 56 ± 39 5 (41.7)
   TNBC 26 9.8 ± 5.3 5.0 ± 3.0 42 ± 35 6 (23.1)
   P = 0.016‡ P = 0.055‡ P = 0.150‡ P = 0.018†
Ki-67      
   Low expression§ 30 6.2 ± 4.1 3.6 ± 2.6 27 ± 65 4 (13.3)
   High expression 41 8.5 ± 4.4 4.0 ± 2.8 49 ± 33 10 (24.4)
   P = 0.018 P = 0.541 P = 0.052 P = 0.367†
  1. HPR, histopathologic responder; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.
  2. * Data are presented as the mean ± standard deviation.
  3. † P-values are based on Chi square or Fisher's exact test.
  4. ‡ P-values are based on Kruskal-Wallis test, otherwise P-values are based on Mann-Whitney U test, presuming to be non-parametric statistics.
  5. § Low expression of Ki-67 was defined as ≤ 5%, and 7 patients were not available for Ki-67 results.
Back to article page